evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,078 questions · 1,098 findings · 33 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 396 · 36.1%GRADE not reported 89 · 8.1%Very low 181 · 16.5%Low 183 · 16.7%Moderate 196 · 17.9%High 53 · 4.8%

Tetracycline vs placebo

Time needed until improvement of the skin lesions · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Tetracycline vs placebo

Duration of remission ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Doxycycline 40 mg vs placebo

HRQOL ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Doxycycline 40 mg vs placebo

Participant‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Metronidazole vs placebo

Duration of remission · Participants with rosacea

Metronidazole probably leads to lower duration of remission compared with placebo (moderate certainty).

1 finding from 1 review

Doxycycline 40 mg vs placebo

Duration of remission ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Azithromycin vs doxycycline

HRQOL ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Azithromycin vs doxycycline

Participant‐assessed improvement in rosacea severity · Participants with rosacea

It is very uncertain whether azithromycin changes participant‐assessed improvement in rosacea severity compared with doxycycline 100 mg (very low certainty).

1 finding from 1 review

Azithromycin vs doxycycline

Proportion of participants with adverse event · Participants with rosacea

It is very uncertain whether azithromycin changes proportion of participants with adverse event compared with doxycycline 100 mg (very low certainty).

1 finding from 1 review

Azithromycin vs doxycycline

Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Azithromycin vs doxycycline

Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Azithromycin vs doxycycline

Time needed until improvement of the skin lesions · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review